/newsroom/taxonomy/term/8844/all en /newsroom/channels/news/breakthrough-ms-treatment-264980 <p>In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.</p> <p>Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of ³ÉÈËVRÊÓƵ, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.</p> Mon, 09 Jan 2017 15:47:38 +0000 laurie.devine@mcgill.ca 26593 at /newsroom